Background: Destabilized transthyretin (TTR) can result in the progressive, fatal disease transthyretin-mediated (ATTR) amyloidosis. A stabilizing TTR mutation, T119M, is the basis for a therapeutic strategy to reduce destabilized TTR. Recently, T119M was associated with extended lifespan and lower risk of cerebrovascular disease in a Danish cohort. We aimed to determine whether this finding could be replicated in the UK Biobank.
Introduction
Transthyretin (TTR), also known as prealbumin, is a homo-tetrameric protein that is primarily synthesized and secreted by the liver but also, to a lesser extent, by the retina and choroid plexus. TTR functions as a major transporter of the vitamin A-retinol binding protein complex, but it also serves a minor role in the transport of thyroxine [1] [2] [3] .
In cases where the TTR gene is mutated or a spontaneous destabilization of the protein occurs, TTR tetramers can dissociate into monomers. These monomers can misfold into amyloid fibrils and form insoluble deposits in multiple tissues including the heart, peripheral nerves, and gastrointestinal tract [4, 5] . Additionally, although less well described, TTR can deposit in cerebral blood vessels (i.e., cerebral amyloid angiopathy) and associated hemorrhagic and ischemic lesions have been noted in a small number of patients [6] [7] [8] [9] . The deposition of TTR amyloid in multiple organs and tissues can result in transthyretin-mediated (ATTR) amyloidosis, a progressively debilitating and life-threatening disease [5, 10, 11] . Two types of ATTR amyloidosis exist: (1) wild-type ATTR amyloidosis, which occurs when no TTR mutation is present and predominantly manifests as cardiomyopathy (although other systems can be involved); and (2) hereditary transthyretin-mediated (hATTR) amyloidosis, where over 120 distinct pathogenic mutations have been identified that serve to destabilize tetrameric TTR, leading to dissociation and subsequent fibril deposition [12, 13] . hATTR amyloidosis results in multisystem disease that can include sensory and motor, autonomic, and cardiac symptoms [14] .
Two mutations encoding a thermodynamically and kinetically stabilized TTR protein have also been described, TTR Thr119Met (T119M; rs28933981) and TTR Arg104His (R104H; rs121918095) [15] [16] [17] [18] . Both variants were discovered in heterozygotes carrying a pathogenic TTR variant in trans with a stabilizing variant, resulting either in a milder pathology or no detectable disease compared with carriers of pathogenic TTR variants alone [19] [20] [21] . When these stabilizing variants are present in combination with pathogenic TTR, the resulting hetero-tetramers demonstrate increased stability in vitro [16, 18, 22] . Specifically, T119M is thought to slow the dissociation of the TTR tetramer by increasing the hydrophobic surface area at the dimer/dimer interface [23] . These observations inspired the discovery of small-molecule TTR tetramer stabilizing therapeutics [24] .
While a few case studies have suggested that T119M and R104H protect against severe manifestations of hATTR amyloidosis, it is not clear whether they have any effect in non-carriers of pathogenic TTR mutations. It has been reported that T119M carriers have higher circulating levels of TTR compared with non-carriers, but no phenotypic associations have been noted for this variant in the genome-wide association catalog despite it being carried by ~1 in 200 people [25, 26] . A previous publication in a Danish population cohort suggested that carriers of T119M may be protected against cerebrovascular disease and have longer lifespan [25] . However, these findings have not been replicated to date.
In the current study, we investigated the potential effect of TTR T119M on vascular disease and mortality in the UK Biobank cohort to assess whether previously documented findings could be replicated.
Methods

Study population
The UK Biobank is a population-based prospective cohort study that recruited ~500,000 participants aged 40-69 years in England, Wales, and Scotland between 2006 and 2010. Participants had to live within 25 miles of one of the 22 assessment centers and participate in a baseline assessment involving the collection of extensive data from questionnaires, health records, physical measurements, imaging, and biologic samples [27] . This analysis included all UK Biobank participants classified as unrelated, white British based on a combination of self-reported ancestry and genetic principal components (n=337,148) [28] . Data used in this analysis were accessed through UK Biobank application 26, 041 and are publicly available upon request to the UK Biobank. The UK Biobank holds ethical approval and all participants provided written informed consent.
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T119M genotyping
Details of the genotyping and quality control process of genetic data in the UK Biobank have been described elsewhere [29] . Briefly, UK Biobank participants were genotyped on either the UK BiLEVE or UK Biobank Axiom array, which share >95% common content. Genotypic data were imputed to the UK10K haplotype, 1000 Genomes Phase 3, and Haplotype Reference Consortium reference panels using SHAPEIT3 [30] for phasing and IMPUTE4 [29] for imputation. The T119M genotype (rs28922981) was imputed with high accuracy (info score=0.925). For cross-sectional analyses, T119M genotype was included in the statistical model as dosages, and for analyses requiring a hard-called genotype, the best-guessed genotype was used.
Ascertainment of disease and death
We analyzed a composite phenotype of vascular disease, defined as a primary or secondary ICD10 diagnoses of I20-I25, I60-I69, or G45, including all child codes of these diagnoses. Additionally, the components of vascular disease (cardiovascular [CV] disease [I20-I25] and cerebrovascular disease [I60-I69 or G45]) as well as the sub-components of cerebrovascular disease (ischemic cerebrovascular disease [I64-I69 and G45]) and hemorrhagic stroke (I60-I63) were also separately analyzed. All ICD10 diagnoses were taken from field 41270 from the UK Biobank data release on 
Covariates
Participant age (field 21,002), sex (field 22,001), and smoking status (field 20,116) were based on self-report at time of enrollment. Body mass index (BMI) (field 21,001) was measured as weight in kilograms divided by height in meters squared (kg/m 2 ) at time of enrollment. Hypertension was defined as a primary or secondary ICD10 diagnosis (field 41,270) of essential hypertension (I10).
Diabetes was defined as a primary or secondary ICD10 diagnosis (field 41,270) of diabetes (E11). 
Statistical analysis
Descriptive statistics are presented as means (standard deviation) for continuous variables and percentages for categoric variables. Continuous and categoric variables were compared between T119M carriers and non-carriers using a t-test and a Pearson chi-square test, respectively.
The association of T119M genotype to death and vascular disease (a composite of CV and cerebrovascular diagnoses) was analyzed using logistic regression and Cox proportional hazards models. Participants with vascular diagnoses prior to UK Biobank study entry, defined as ICD10 diagnosis of disease between 1996 and enrollment date, were removed from the prospective time to Age at death or diagnosis of first vascular disease was compared between T119M and noncarriers using a t-test. For participants that were diagnosed with a vascular disease and subsequently died, the number of years they survived post diagnosis was compared using a t-test. Table 1 shows the baseline characteristics of the 337,148 participants included in this study. A total of 2502 UK Biobank participants carried the T119M allele, distributed as 2499 heterozygotes and three homozygotes (minor allele frequency=0.4%). T119M carriers were less likely to be smokers than non-carriers (p=.02) but the two groups were similar in terms of age, sex, and other CV risk factors ( Table 1) .
Results
Baseline characteristics
Association of TTR T119M genotype with vascular disease and death
The association of T119M genotype with death and vascular disease was investigated using logistic regression controlling for age, sex, smoking status, BMI, and genetic ancestry. There was a total of 13,680 deaths and 36,024 vascular disease diagnoses captured in the UK Biobank. No significant association was identified with any of the outcomes examined, namely, death, all vascular disease, CV disease, cerebrovascular disease, ischemic vascular disease, or hemorrhagic stroke (Figure 1) , or with any of the constituent diseases that these compound outcomes are composed of ( Supplemental   Table S1 ). Similarly, no significant association of T119M genotype was identified with any outcome examined after additionally controlling for hypertension, diabetes, LDL, HDL, triglycerides, and CRP (Supplemental Table S2 ).
TTR T119M genotype and risk of vascular disease and death in time to diagnosis analysis
In addition to the cross-sectional analysis, a Cox proportional hazards analysis was used to investigate whether an association exists between the T119M genotype and risk of death or vascular disease. On average, UK Biobank participants were followed for 8.9 years (range: 0-11.9 years) and were 65.7 years old at censoring (range: 40.6-81.1 years) (Supplemental Figures S1 and S2) . Loss to followup over the study period was minimal (0.2%) and did not differ by T119M genotype (p=.5). Prevalent diagnoses occurring before a patient's date of enrollment were removed, resulting in 19,804 vascular disease diagnoses and 13,680 deaths over a total of 2,959,979 person-years of follow-up. No deaths or vascular disease diagnoses occurred in the three T119M homozygotes. Cox proportional hazards regression controlling for age, sex, BMI, smoking, and genetic ancestry revealed no difference between T119M carriers and non-carriers in their risk of death or vascular disease, including CV, cerebrovascular, hemorrhagic stroke, and ischemic cerebrovascular disease (Figure 2) . This also remained true after controlling for hypertension, diabetes, LDL, HDL, triglycerides, and CRP (Supplemental Table S3 ). Vascular disease diagnoses occurred in 6.2% of T119M carriers and 5.9% 9 of non-carriers; survival time to first vascular disease diagnosis was not lengthened in T119M carriers (HR=1.06; 95% CI = 0.8-1.2; p=.45) (Figure 3) .
T119M genotype and age at death and survival following diagnosis of vascular disease
The mean age at death from all causes was similar between T119M carriers and non-carriers (p=. 12) and no difference was seen in age at first diagnosis of vascular disease (p=.38), including cardiovascular disease (p=.72) and cerebrovascular disease (p=.41) (Figure 4) . For participants who were diagnosed with any vascular disease and subsequently died (n=4180), there was no significant difference between T119M carriers and non-carriers in their survival time following vascular disease diagnosis (p=.82), including CV disease (p=.84) and cerebrovascular disease (p=.41) ( Table 2 ).
Discussion
In a large prospective cohort study of 337,148 participants of the UK Biobank, carriers of the TTR T119M mutation were not found to be protected against vascular disease, cerebrovascular disease, CV disease, or death (p>.05, OR/HR >1 for all analyses). Furthermore, no difference was seen between T119M carriers and non-carriers in their time to death following a diagnosis of vascular disease (including CV and cerebrovascular disease). Together, these findings suggest stabilization of the TTR tetramer via the T119M mutation is not beneficial in a general population setting in terms of mortality and vascular disease.
These findings are notable given a previous report from a Danish cohort showing T119M carriers were protected against vascular disease and have longer lifespans than non-carriers [25] . In that study, the authors compared 321 T119M heterozygotes to ~68,000 non-carriers in a cohort containing 10,636 incident vascular diagnoses spanning an average follow-up of 32 years. The current study offered a larger sample size (2502 T119M carriers and 334,646 non-carriers) and, therefore, greater statistical power to detect associations between T119M genotype and vascular disease or death. This current study has 98% power to detect an association with vascular disease with OR of 0.83 compared with 52% power in the study by Hornstrup et al. [25, 31] . Overall, the UK Biobank 1 0 includes 7.8 times more T119M carriers (2502 vs. 321) and 3.4 times more vascular diagnoses.
Moreover, the study by Hornstrup et al. [25] had a small number of diagnoses within the T119M carriers (n=37 vascular diagnoses, 29 cardiovascular diagnoses, and 11 cerebrovascular diagnoses).
Additionally, there are other methodologic differences that may explain the contrasting results. In the present study, related subjects were removed from the analyses, and genetic principal components were used to control for population stratification in the regression models, both of which are factors which, if not accounted for, can lead to false positive results. The mean follow-up time of individuals was different between the studies (mean of 8.9 years in the current study versus 32 years in the previous report). However, given there are 7.8 times more carriers and 3.4 times more diagnoses in this analysis, it is not clear whether length of follow-up would be expected to provide an explanation for the observed differences. Finally, geographic differences, including diet, lifestyle, and climate, may also have an effect as these two studies were performed in different populations.
These results raise questions concerning what, if any, physiologic effects the TTR T119M mutation confers to the general population. However, the biochemical effects of this variant are clear; threonine 119 sits within the deepest of the three halogen binding pockets of the T4 binding site created by the dimer-dimer interface in TTR. The substitution of methionine at this position introduces additional hydrophobicity in the pocket, inducing additional contacts between the different dimers at this interface, resulting in enhanced kinetic stability [15] [16] [17] [18] 21] . In the context of the carriers of hATTR amyloidosis-associated TTR gene mutations, compound heterozygotes of pathogenic TTR variants and the T119M variant displayed no or mild clinical symptoms of hATTR amyloidosis in a small case study, indicating a potential protective effect of the T119M mutation in this group [20] . Additionally, as a therapeutic strategy in patients with ATTR amyloidosis, TTR stabilizers mimicking the T119M mutation have shown clinical benefits [32, 33] . However, a growing body of literature indicates that patients treated with TTR stabilizer therapies continue to experience disease progression [34] [35] [36] [37] [38] [39] [40] indicating that TTR stabilization (at least with current molecules) may not be enough to stabilize or halt disease. 1 1 In summary, no association was found between T119M genotype and risk of vascular disease or death in a large-scale prospective cohort study of 337,148 participants. This suggests that stabilization of TTR through the T119M mutation does not confer general protection against vascular disease or death. Further research is needed to understand the role of TTR stabilization in ATTR amyloidosis pathogenesis as there is growing interest in treating patients with ATTR amyloidosis, including earlier intervention in identified carriers of pathogenic TTR mutations. Supplementary material Supplemental Table S1 . Cross-sectional association analysis of subjects with versus without the of T119M genotype and ICD10 codes that define vascular disease. Association was tested using logistic regression controlling for age, sex, smoking status, body mass index, and genetic ancestry via principal components. Codes with at least 100 diagnoses were tested for association. 
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